Single Subcutaneous Dose Rising Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of NNC 0070-0002-0349 [obesity therapies] in Overweight/Obese Male Subjects.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2012
At a glance
- Drugs NNC 0070-0002-0349 (Primary)
- Indications Obesity
- Focus Adverse reactions
- 16 Oct 2008 Planned end date changed from 1 Nov 2008 to 1 Oct 2008 as reported by ClinicalTrials.gov.
- 16 Oct 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 23 Aug 2008 New trial record.